Predictors of Drug-Resistant Tuberculosis among High-Risk Population Diagnosed under National Program Conditions in the Littoral Region, Cameroon

Teyim Pride Mbuh, Adeline Wandji, Liliane Keugni, Sandrine Mboh, Irene Ane-Anyangwe, Wilfred Fon Mbacham, and Henry Dilonga Meriki

1Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Cameroon
2Tuberculosis Reference Laboratory Douala, Cameroon
3Littoral Regional Technical Group for the Control of Tuberculosis/Littoral Regional Delegation for Public Health, Cameroon
4Biotechnology Centre of Nkolbisson, University of Yaounde I, Cameroon

Correspondence should be addressed to Henry Dilonga Meriki; merilonga@yahoo.com

Received 2 October 2020; Revised 21 April 2021; Accepted 19 October 2021; Published 19 November 2021

1. Introduction

Tuberculosis (TB) is a communicable disease caused by Mycobacterium tuberculosis complex and transmitted principally by the respiratory route. Globally, persons with an immune compromised HIV/AIDS status are more likely (17-23 times) to develop TB in a lifetime than those who are immune competent [1]. Drug-resistant tuberculosis is a global health challenge that threatened the progress of tuberculosis eradication programs in the world and particularly in Africa. The World Health Organization (WHO) defines MDR-TB as strains of Mycobacterium tuberculosis that are resistant to isoniazid and rifampicin, with or without resistance to other first-line drugs [2], and factors, such as the usage of immunosuppressive drug, HIV/AIDS, smoking, alcohol usage, diabetes mellitus, malnutrition, young age,
overcrowding, poor housing conditions, and economic deprivation have been associated as predictors of drug-resistant TB [1]. Drug resistance surveillance data show that 3.9% of new and 21% of previously treated TB cases were estimated to have had MDR/RR-TB in 2015 [3]. There was some progress made in testing and detection of MDR/RR-TB cases in the year 2018, literature review shows that globally in 2018, 51% of persons with bacteriologically confirmed TB were tested for rifampicin resistance, and as much as 41% in 2017 [4]. Testing coverage of 46% for new and 83% for previously treated TB patients was recorded, and a global total of 186,772 cases of MDR/RR-TB were detected and notified in 2018 [4].

Despite this progress made, the number of persons on TB treatment in 2018 was equivalent to only one-third of those who developed MDR/RR-TB in 2018. Amongst the many possible ways of closing this gap is the need for an increase in the coverage of testing for drug resistance among bacteriologically confirmed cases, accurate and early detection of drug-resistant tuberculosis is essential for effective patient care, for preventing the development of drug-resistant strains of tuberculosis. Culture-based drug susceptibility tests are the recommended methods for the detection of drug-resistant tuberculosis, but they are time-consuming and technically challenging, especially in resource-limited settings [5]. Many nucleic acid amplification assays that detect mutations associated with anti-TB drug resistance have been developed recently, to provide affordable, accurate, simple, and rapid diagnostic tests for DR-TB detection. Cameroon was one of the leading African countries that introduce nucleic acid amplification-based assays in the National Tuberculosis Program, and the Gene Xpert MTB/RIF and Line Probe assays were introduced in the Littoral region in 2014.

According to the WHO Global Report on antituberculosis drug resistance in the World for years [6, 7], MDR-TB strains have emerged in all regions of the world. However, despite, the African continent accounting for over a quarter of new TB cases among people living with TB, MDR-TB appears nearly absent from this continent, which, until recently, reported the lowest median levels of drug resistance TB [8]. Two explanations can be put forward to explain these reported low levels of MDR-TB in the African Continent. The first is the lack of data on drug-resistant TB in most African Countries [8], and the second is the recent introduction of rifampin in Africa. It is often stated that because rifampin was only recently introduced in Africa on a large scale, there has been relatively little time for resistance to develop. However, the development of rifampin resistance may be spurred by HIV infection, and such resistance appears to develop rapidly [8].

This study was therefore conducted to determine the incidence of MDR-TB and XDR-TB and also to predict indicators of drug resistance-TB amongst patients seeking medical attention in the Littoral Region of Cameroon.

2. Methods

2.1. Study Design and Population. We used a descriptive cross-sectional hospital-based epidemiological survey to screen 3492 participants who were either strong clinical suspects for TB having a smear negative result at the peripheral laboratories or presenting with symptoms of TB having a pre-TB treatment exposure from January 2016 to December 2017. One hundred and ninety (190) were rejected because of incomplete questionnaires or poor specimen quality. A total of 3302 were enrolled. The Littoral region was chosen because it harbors about 20% of all TB diagnosed cases in Cameroon and also because it is the economic headquarters of Cameroon and Douala; the regional headquarters is the largest city in Cameroon with a population of 3,663,000 people [9]. It harbors many referral diagnostic and treatment institutions that pull many persons from the regions in search of better health services.

2.2. Laboratory Variables. A total of 3302 (3057 sputum specimens and 245 non-sputum specimens (sputum, pleural fluid, cerebrospinal fluid, synovial fluid, ascites, and lymph node aspirate) obtained from participants for this study from 32 (82.1%) of the 39 DTCs. They were decontaminated using 3% NaOH, and the pellet used for TB diagnosis by liquid culture (Recton, Dickson and Company, USA, BACTEC 960) for 42 days, LJ slant, was incubated (MIE800, Ine 800, Germany) at 37°C for eight consecutive weeks and by Gene Xpert MTB/RIF (Cepheid, France). The Gene Xpert system integrates and automates sample processing, nucleic acid amplification, and detection of the target sequences. The primers in the Gene Xpert MTB/RIF assay amplify a portion of the rpoB gene containing the 81 base pair “core” region. The probes can differentiate between the conserved wild-type sequence and mutations in the core region that is associated with rifampicin resistance (RR). All procedures were performed following manufacturer instructions.

A total 3492 participants were recruited for this study, and 1665 were analyzed for initial drug susceptibility testing (DST) which was rifampicin by Gene Xpert MTB/RIF. Rifampicin resistance cases were further subjected to line probe assay (LPA), Hain Lifescience, Nehren, Germany GenoType MTBDRplus and GenoType MTBDRsl assays (Applied Biosystems thermocycler, Life technologies, 2012, Singapore), and DST testing for isoniazid, rifampicin, fluoroquinolones, and injectable aminoglycosides (kanamycin, amikacin, and capromycin).

Following the national policy on HIV testing, all persons with signs and symptoms of TB were offered an HIV test. This was performed following standard national protocols. Briefly, 0.5 ml of plasma was transferred to the absorbent pad of the Determine HIV 1/2 test strip. Positive samples were confirmed on rapid SD Bioline HIV 1/2 3.0 cassettes.

2.3. Outcome Variables. Rifampicin resistant-TB case was defined as a TB case diagnosed with resistance to rifampicin, MDR-TB case was a TB case diagnosed with resistance to at least isoniazid and rifampin, pre-XDR-TB was defined as MDR-TB with resistance to either a fluoroquinolone or a second-line injectable agent but not both, and XDR-TB was a TB case diagnosed with resistance to isoniazid and rifampin, plus any fluoroquinolone and at least one of three
injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin).

2.4. Independent Variables. Data on demographics (sex, age), clinical (fever, cough, weight loss, and night sweat), socioeconomic (marital status, monthly income below 50,000 FCFA), behavioral (alcohol consumption and cigarette smoking), previous contact with TB cases, and incarceration were obtained using structured questionnaires. A new case was any tuberculosis case that had never taken antituberculosis or treated for less than a month; a relapse was any patient having a second episode of TB; a therapeutic failure was a case whose smear remained or became positive again in the 5th month or later during TB treatment. We adapted the scoring system from a study by de Castro et al. (2011) [10] to assess the association between clinical evidence of TB and the final TB outcome. The variables considered were old age (≥59 years), cough (involuntary, spasmodic, and particularly audible expulsion of breathed air caused by foreign bodies in the larynx or irritation of the mucosa in the trachea and bronchi), weight loss (loss of 3 kg in individuals weighing up to 70 kg and loss of 5 kg in those over 70 kg); fever (body temperature above 37.5°C); night sweats (excessive sweating during the night soaking bedclothes and/or bedding), hemoptysis (expectoration of bright red blood); a history of TB (haven’t been treated with anti-TB drugs for at least two months), and a total score of ≥7 signified strong clinical evidence for TB disease as described on Table 1.

2.5. Ethical Statement. Administrative authorizations for this study were obtained from the permanent secretary for the National Tuberculosis Control Program, and ethical clearance was obtained from the University of Douala ethical review board (No: 1255 IEC-Udo/02/2018/T).

2.6. Data Analysis. Data analysis was carried out using SPSS 24.0 (Statistical Package for the Social Sciences, Chicago, Illinois). Univariate analysis was performed with chi-square, and all variables were included in the logistic regression model. Statistical significance was set at p < 0.05.

3. Results

A total of 3492 participants were enrolled from January 2016 to December 2017 in the Littoral region of Cameroon. A total of 190 (5.6%) participants were not analyzed because of incomplete questionnaires and/or poor sample quality. Overall, 3302 were analyzed among whom 1665 (50.4%) patients were tested positive for Mycobacterium tuberculosis as illustrated in Figure 1.

3.1. Sociodemographic Characteristics Mycobacterium tuberculosis-Infected Participants. The age of participants ranged from 1 to 90 years with a mean age of was 35.85 ± 13.91 years’ standard deviation. Most of the participants were male (51.2%) and between the age group 31 and 45 years old (38.4%). Over fifty percent (55.5%) were married, and 17.8% were incarcerated. A total of 71.6% of the participants had been previously infected with tuberculosis of which 63.7% were relapsed cases. The location of the disease was pulmonary (96.4%) in most of the participants, and 26.4% were HIV-positive individuals (Table 2).

3.2. Signs and Symptoms of Study Participants at Enrolment. Seven specimen types (spumum, bronchoalveolar lavage, cerebrospinal fluid, ascites, lymph node aspirate, pleural, and pericardial fluids) were analyzed in this study with sputum [1543 (92.7%)] being the most frequent followed by bronchoalveolar lavage (3.7%). Cough (98.3%, n = 1636) was the most frequent among symptoms presented by participants. A total of 151 (9.1%) patients had all the four cardinal symptoms (cough, weight loss, night sweats, fever) for tuberculosis as illustrated on Figure 2.

3.3. Prevalence of RR-TB, MDR, and XDR-TB. Of the 1665 patients enrolled, we identified 37 [(11.4%) with previous history for TB and (11.1%) without previous History for TB] and 49 [(1.7%) with previous history for TB and (4.6%) without previous History for TB] cases of rifampicin resistance TB (RR-TB) in 2016 and 2017, respectively, making a total of 86 (5.2%) cases of rifampicin resistance. More (11.3%) cases of drug resistance were diagnosed in 2016 compared to 2017 (3.7%). And 11 (0.7%) of them were resistant to rifampicin only. A total of 75 (4.5%) were to both rifampicin and isoniazid (MDR-TB). Of this MDR-TB, 2.7 (2/75) and 1.3% (1/75) were pre-XDR and extensive drug resistance TB (XDR-TB), respectively (Figure 3).

3.4. Predictors of Occurrence Drug Resistance TB (All Forms) among Study Participants. The mean age of participants with drug resistance in this study was 38.2 ± 14.3 years, and drug resistance univariate analysis showed that TB drug resistance increased with age with participants older than 60 years having a more than 4 times risk (OR = 4.98, p = 0.047) compared to those younger than 16 years. Similarly, married participants recorded more drug resistance TB than unmarried (OR = 1.91, p = 0.006) participants. Although not significant (OR = 0.50, p = 0.27), drug resistance was predominant among male participants. More drug resistance TB was recorded in the years 2016 than 2017 (11% versus 3.7%, p < 0.001). Being incarcerated was significantly associated with developing drug resistance (OR = 1.74, p = 0.027). Drug resistance was detected two times more amongst those who had contacts with known TB cases than those who did not.
not have contacts (8% versus 4%, $p = 0.007$). Drug resistance was predominant, though, not significant amongst those with previous TB history (OR = 1.26, $p = 0.382$) as illustrated in Table 3.

4. Discussion

Drug-resistant tuberculosis is rising to critically high levels in all parts of the world, and new resistance mechanisms are emerging and spreading globally, threatening our ability to treat the disease. Antibiotic resistance leads to higher medical costs, prolonged hospital stays, and increased mortality. Contemporary data are constantly needed in the monitoring and rational decision-making towards the reduction of TB drug resistance.

This study which mainly targeted suspected patients with TB diagnostic challenges showed that the majority of 1230 (73.9%) of the study participants were preexposured to TB treatment. This was similar to our previous study in the Littoral region of Cameroon [11] but different from that of Meriki et al. [12] in the South West of Cameroon where 88.3% of the study participants were newly diagnosed cases. The prevalence of RR-TB and MDR-TB in this study was 5.2% and 4.8%, respectively. This prevalence is in concordance with global MDR-TB estimates of 2015-2018 [13, 14], however, lower than that report by Jürgen et al. [15] in Cameroon. To the best of my knowledge, Cameroon has not organized a national drug susceptibility testing survey to evaluate drug resistance nationwide. National strategy for drug susceptibility testing in Cameroon from 2009 to 2017 consisted of testing only retreatment cases for drug

---

**Figure 1:** Study profile of participant enrolment and testing.
The proportion of retreatment cases tested for drug susceptibility moved from 16% in 2009 to 85% in 2017 and the cases diagnosed with MDR-TB moved from 19% in 2009 to 24% in 2011. Since then, it has systematically reduced and was at 13% in 2017 [16]. This data is similar to our findings which demonstrate that RR-TB among retreatment cases reduced from 11.4% in 2016 to 4.6% in 2017. This find could probably be explained by the fact that Gene Xpert was introduced in Cameroon in 2014, and this has led to an improvement in TB case management in Cameroon such that RR-TB cases are diagnosed and treatment early. In this study, RR-TB cases were detected more from TB relapsed (5.7%), failure (4.8%), and newly diagnosed cases (4.4%). Those with pre-TB treatment exposure from whom RR-TB was detected represented 77.9% (67 cases) of all the RR-TB cases. The proportion of RR-TB cases reported in this study is higher than the global average in 2016-2018 [13, 14]. Cameroon being a high HIV burden nation could be an explanation for this observation. In this study, 6.4% of RR-TB cases were coinfected with HIV-1. Studies have

### Table 2: Sociodemographic characteristics of 1665 Mycobacterium tuberculosis infected participants in the littoral region of Cameroon.

| Characteristics          | Categories          | Frequency | Percentage (%) |
|-------------------------|---------------------|-----------|----------------|
| Gender                  | Female              | 612       | 36.8           |
|                         | Male                | 1053      | 63.2           |
| Age groups (years)      | <16                 | 94        | 5.6            |
|                         | 16-30               | 566       | 34.0           |
|                         | 31-45               | 640       | 38.4           |
|                         | 46-60               | 283       | 17.0           |
|                         | > 60                | 82        | 4.9            |
| Marital status          | Single              | 741       | 44.5           |
|                         | Yes                 | 297       | 17.8           |
| Current incarceration   | No                  | 1368      | 82.2           |
| Income level (XAF)      | < 50 000 (~100 USD) | 1376      | 82.6           |
|                         | 50,000-100,000      | 120       | 7.2            |
|                         | > 100,000           | 169       | 10.2           |
| New cases               | 435                 | 26.1      |
| Defaulters              | 70                  | 4.2       |
| Patient category        | Failure             | 63        | 3.8            |
|                         | Relapse             | 1097      | 65.9           |
| Location of TB          | Extrapulmonary TB   | 60        | 3.6            |
|                         | Pulmonary TB        | 1605      | 96.4           |
| HIV-1 status            | Negative            | 1225      | 73.6           |
|                         | Positive            | 440       | 26.4           |

**Figure 2:** Signs and symptoms in study participants.
shown that the immunocompromised state of HIV patients predisposes them to recurrent TB episodes [17]. HIV patients receiving ART are also at high risk of poor TB treatment adherence due to the high pill burden they take [18]. Some ART drugs have also been documented to have adverse outcomes when administered with anti-TB drugs [18]. These factors combined and increase the risk of failing treatment and developing RR-TB.

Patients with pre-TB treatment exposure were more likely to have RR-TB as compare to new suspects. This finding was in line with that of Ullah [19] who found that the frequency of drug resistance in previously treated TB suspects is 5 times higher than those of newly diagnosed cases. The resistance in new suspects may be indicative of the transmission of resistant strains of the bacilli, while resistance in previously treated cases may be an indicator of poor compliance, lack of treatment supervision, and ineffective TB Control Programme.

Unlike many studies that have demonstrated an association between gender and MDR-TB [20–22], the current study did not show an association between gender and RR-TB. In this study, RR-TB cases were predominantly young with a mean age of 38.2 ± 14.3 years. These findings were similar to those of other studies in Africa [23, 24]. Although a majority of RR-TB patients in the present study belonged to the younger age group (15–45 years), the risk of RR-TB was seen to be almost four times higher among elderly individuals (age>60 years), which concords with the findings of some authors [25, 26] but contrasts with those of others [27, 28] but lower with adjusted odds ratios. This drug resistance data stratified by age is very important in surveillance of drug-resistant trends in a given setting since a high proportion of drug-resistant cases in young age groups could be indicative of recent transmission as opposed to that in older age groups. High proportions of drug resistance in older age groups could be an indicator of the reactivation of old infections.

Over one billion people are reported to be smokers worldwide, 80% of them reside in low- and middle-income countries, many of which also have a high TB burden [29]. In this study, active smoking was not significantly associated with RR-TB but many studies have shown that smoking is significantly associated with increased risks of tuberculous infection [30], morbidity, treatment outcomes [31], and drug resistance [3]. The role that cigarette smoke plays in the pathogenesis of tuberculosis is related to ciliary dysfunction, to a reduced immune response, and defects in the immune response of macrophages, with or without a decrease in the CD4 count, increasing susceptibility to infection with Mycobacterium tuberculosis [32], though we did not find any link between cigarette smoking and drug resistance, we think an increase primary and secondary TB transmission, TB relapse, and poor treatment compliance would eventually result in drug resistance. This situation can however be avoided by improving compliance to TB treatment and the application of measures to promote the cessation of smoking.

According to WHO [33], poverty is a strong predictor of TB. New TB infection is not just the product of poverty, but also creates poverty. Understanding the connection between TB and poverty is an important first step towards breaking this vicious cycle. Fighting TB and poverty together is necessary to accelerate economic and social growth and consequently reduce the global burden of TB. In this study, though there was no significant association between monthly income below 50,000 FCFA and TB infection. Persons with incomes of less than 50,000 FCFA predominantly developed RR-TB. Poverty facilitates the transmission of Mycobacterium tuberculosis, primarily through (1) its influence on living conditions, such as people living in overcrowded and poorly ventilated homes, (2) prolonged diagnostic delay, and (3) increased vulnerability due to malnutrition and/or HIV infection. Some studies have equally argued that beyond a certain threshold, the exact level of poverty has little influence on transmission risk since living conditions remain conducive. Such studies [34] lay more importance on living conditions rather than the exact level of poverty.

This study reveals that incarceration was statistically associated with RR-TB development. This finding was in line with other studies [35, 36] which show that incarceration was a risk factor for developing TB and subsequent drug

![Drug resistance profile of study participants. TB: tuberculosis; RR: rifampicin resistance; MDR: multidrug resistance; XDR: extensive drug resistance.](image-url)
resistance. WHO [37] reports show that the level of TB in some prisons is 100 times higher than that of the civilian population and may account for up to 25% of a country’s burden of TB with 24% of these cases developing MDR-TB. Factors such as poverty, late diagnosis, inadequate treatment, overcrowding, poor ventilation, and repeated prison transfers may encourage the transmission of TB infection and subsequent drug resistance.

Multivariate analysis of all the factors demonstrates only previous contact with TB patient and year of enrolment that were independent associated with RR-TB. This indicates that before the introduction of the Gene Xpert MTB/RIF and Line Probe assays, drug resistance rates were high more than 3 times in 2016 compared to 2017.

### 5. Conclusion

In univariate analysis, this study shows that age greater than 60 years, being married, and incarcerated are predictors of drug resistant-TB, while the year of patient enrolment and

| Characteristics               | Resistant | Sensitive | Crude odds ratio (95% CI) | p value | Adjusted odds ratio (95% CI) | p value |
|-------------------------------|-----------|-----------|---------------------------|---------|-----------------------------|---------|
| Gender                        |           |           |                           |         |                             |         |
| Female                        | 37 (4.6)  | 776 (95.4)| 1                         |         | 1                           | 1       |
| Male                          | 49 (5.8)  | 803 (94.2)| 1.28 (0.83–2.0)           | 0.27    | 1.18 (0.73-1.93)             | 0.50    |
| Age group (years)             |           |           |                           |         |                             |         |
| < 16                          | 2 (2.1)   | 92 (97.9)| 1                         |         |                             |         |
| 16-30                         | 28 (4.9)  | 538 (95.1)| 2.08 (0.91-4.72)          | 0.081   | 1.87 (0.75-4.65)             | 0.177   |
| 31-45                         | 30 (4.7)  | 610 (95.3)| 2.20 (0.97-4.98)          | 0.059   | 2.05 (0.85-4.95)             | 0.110   |
| 46-60                         | 18 (6.4)  | 265 (93.6)| 1.59 (0.67-3.80)          | 0.296   | 1.30 (0.52-3.23)             | 0.575   |
| >60                           | 8 (9.8)   | 74 (90.2)| 4.98 (1.02-24.39)         | 0.047   | 2.67 (0.51-14.1)             | 0.244   |
| Marital status                |           |           |                           |         |                             |         |
| Single                        | 26 (3.5)  | 715 (96.5)| 1                         |         |                             |         |
| Married                       | 60 (6.5)  | 864 (93.5)| 1.91 (1.19-3.06)          | 0.006   | 1.51 (0.89-2.55)             | 0.128   |
| Year of enrolment             |           |           |                           |         |                             |         |
| 2017                          | 49 (3.7)  | 1288 (96.3)| 1                         |         |                             |         |
| 2016                          | 37 (11.3) | 291 (88.7)| 3.34 (2.14-5.22)          | < 0.001 | 3.21 (2.01-5.11)             | < 0.001 |
| Incarceration                 |           |           |                           |         |                             |         |
| No                            | 63 (4.6)  | 1305 (95.4)| 1                         |         |                             |         |
| Yes                           | 23 (7.7)  | 274 (92.3)| 1.74 (1.06-2.85)          | 0.027   | 1.55 (0.83-2.92)             | 0.169   |
| Income level (XAF; 50,000 XAF = ~ 100 USD) | | | | | | |
| >100,000                      | 10 (5.9)  | 159 (94.1)| 1                         |         |                             |         |
| 50,000-100,000                | 8 (6.7)   | 112 (93.3)| 1.14 (0.44-2.97)          | 0.795   | 1.48 (0.52-4.21)             | 0.462   |
| <50,000                       | 68 (4.9)  | 1308 (95.1)| 0.83 (0.42-1.64)          | 0.585   | 1.03 (0.50-2.14)             | 0.938   |
| Previous TB history           |           |           |                           |         |                             |         |
| No                            | 19 (4.4)  | 416 (95.6)| 1                         |         |                             |         |
| Yes                           | 67 (5.4)  | 1163 (94.6)| 1.26 (0.75-2.12)          | 0.382   | 1.10 (0.59-2.04)             | 0.776   |
| HIV-1 status                  |           |           |                           |         |                             |         |
| Negative                      | 58 (4.7)  | 1167 (95.3)| 1                         |         |                             |         |
| Positive                      | 28 (6.4)  | 412 (93.6)| 1.37 (0.86-2.18)          | 0.185   | 1.39 (0.86-2.25)             | 0.179   |
| Previous contacts with a TB case |         |           |                           |         |                             |         |
| No                            | 58 (4.4)  | 1256 (95.6)| 1                         |         |                             |         |
| Yes                           | 28 (8.0)  | 323 (92.0)| 1.88 (1.18-3.0)           | 0.007   | 1.90 (1.17-3.10)             | 0.010   |
| Smoking                       |           |           |                           |         |                             |         |
| No                            | 71 (5.5)  | 1209 (94.5)| 1                         |         |                             |         |
| Yes                           | 15 (3.9)  | 370 (96.1)| 0.69 (0.39-1.22)          | 0.199   | 0.59 (0.32-1.09)             | 0.093   |
| Alcohol                       |           |           |                           |         |                             |         |
| No                            | 35 (4.4)  | 760 (95.6)| 1                         |         |                             |         |
| Yes                           | 51 (5.9)  | 819 (94.1)| 1.35 (0.87-2.10)          | 0.179   | 1.20 (0.74-1.94)             | 0.470   |
previous exposure to TB treatment were independent predictors of drug resistance in the Littoral region of Cameroon. Though this work was limited to molecular techniques for drug resistance detection and could result in underreporting of drug resistance strains, it remains valid because it highlights the presence of rifampicin-resistant-TB, multidrug-resistant TB, and extensive drug-resistant TB cases.

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

Special thanks are due to the permanent secretary of the National Tuberculosis Program in Cameroon who permitted us to work in 15 of the 39 diagnostic and treatment centers in the Littoral region. We also use this opportunity to thank all the staffs of the 15 diagnostic and treatment centers who assisted us with specimen collection drug administration and treatment monitoring.

References

[1] WHO, HIV-Associated Tuberculosis, 2018, https://www.unaids.org.
[2] WHO, What is multidrug-resistant tuberculosis (MDR-TB) and how do we control it?, 2018.
[3] WHO, Global tuberculosis control, 2016, https://apps.who.int/iris/handle/10665/250441.
[4] WHO, "Global Tuberculosis Report," 2019, http://www.who.int/tb/data.
[5] T. N. A. Nguyen, V. Anton-le Berre, A. L. Banuls, and T. V. A. Nguyen, "Molecular diagnosis of drug-resistant tuberculosis; a literature review," Frontiers in Microbiology, vol. 10, 2019.
[6] WHO, "Global tuberculosis report, 2015," https://apps.who.int/iris/handle/10665/191102.
[7] WHO, Anti-tuberculosis resistance in the world, Report no. 4, Geneva, Switzerland, 2008.
[8] Y. Ben Amor, B. Nemser, A. Singh, A. Sankin, and N. Schluger, "Underreported threat of multidrug-resistant tuberculosis in Africa," Emerging Infectious Diseases, vol. 14, no. 9, pp. 1345–1352, 2008.
[9] D. Macrotrends, "Cameroon Metro Area Population 1950-2020," https://www.macrotrends.net/cities/20362/douala/population.
[10] C. B. de Castro, P. da Costa, A. Ruffino-Netto, E. L. Maciel, and A. L. Kritski, "Assessment of a clinical score for screening suspected pulmonary tuberculosis cases," Revista de Saúde Pública, vol. 45, no. 6, pp. 1110–1116, 2011.
[11] T. P. Mbuh, I. Ane-anyangwe, W. Adeline, B. D. T. Pokam, H. D. Meriki, and W. F. Mbacham, "Bacteriologically confirmed extrapulmonary tuberculosis and treatment outcome of patients consulted and treated under program conditions in the littoral region of Cameroon," BMC Pulmonary Medicine, vol. 19, no. 17, pp. 1–7, 2019.
[12] H. D. Meriki, K. A. Tufon, P. N. Atanga et al., "Drug resistance profiles of Mycobacterium tuberculosis complex and factors associated with drug resistance in the Northwest and Southwest regions of Cameroon," PLoS One, vol. 8, no. 10, 2013.
[13] WHO, "Resistant TB (MDR/RR-TB): Update 2017 The global TB situation," no. 1, pp. 1–34, 2017.
[14] WHO, Global Tuberculosis Report 2018, 2018, https://apps.who.int/iris/handle/10665/274453.
[15] J. Noeske, N. Voelz, E. Fon, and J. L. Abena Foe, "Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon," BMC Research Notes, vol. 5, no. 1, p. 160, 2012.
[16] A. Enoka, Appui à l’amélioration de la performance du volet diagnostique et prise en charge de la TB-RR/MR au Cameroun - un Bilan (FEI-5%: Mission n° 16SANIN120), pp. 12-13, 2018.
[17] A. C. Crampin, J. N. Mwaungulu, F. D. Mwaungulu et al., "recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi," AIDS, vol. 24, no. 3, pp. 417–426, 2010.
[18] A. Finlay, J. Lancaster, T. H. Holtz, K. Weyer, A. Miranda, and M. WoltVan Der, "Patient- and provider-level risk factors associated with default from tuberculosis treatment, South Africa, 2002: a case-control study," BMC Public Health, vol. 12, no. 1, p. 56, 2012.
[19] I. Ullah, A. Javaid, Z. Tahir et al., "pattern of drug resistance and risk factors associated with development of Drug Resistant Mycobacterium tuberculosis in Pakistan," PLoS One, vol. 11, no. 1, article e0147529, 2016.
[20] M. Eijaz, A. R. Siddiqui, Y. Rafiq et al., "Prevalence of multidrug resistant tuberculosis in Karachi, Pakistan: identification of at risk groups," Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 104, no. 8, pp. 511–517, 2010.
[21] N. Lomtadze, R. Aspindzelashvili, M. Janjgava et al., "Prevalence and risk factors for multidrug-resistant tuberculosis in the republic of Georgia: a population-based study," The International Journal of Tuberculosis and Lung Disease, vol. 13, no. 1, pp. 68–73, 2009.
[22] Z. Mor, D. Goldblatt, H. Kaidar-Shwartz, N. Cedar, E. Rorman, and D. Chemtob, "Drug-resistant tuberculosis in Israel: risk factors and treatment outcomes," The International Journal of Tuberculosis and Lung Disease, vol. 18, no. 10, pp. 1195–1201, 2014.
[23] S. Adwani, U. D. Desai, and J. M. Joshi, "Prevalence of pre-extensively drug-resistant tuberculosis (pre XDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) among pulmonary multidrug-resistant tuberculosis (MDR-TB) at a Tertiary Care Center in Mumbai," The Journal of Krishna Institute of Medical Sciences University, vol. 5, no. 3, pp. 4231–4261, 2016.
[24] O. Daniel, E. Osman, O. Oladimeji, and O. G. Dairo, "Pre-extensive drug-resistant tuberculosis (pre-XDR-TB) among MDR-TB patients in Nigeria," Global Advanced Research Journal of Microbiology, vol. 2, pp. 315–5116, 2013.
[25] O. Korotych, A. Hovhannisyan, O. Zaitseva, O. Denisik, A. Dadu, and M. Dara, "Risk factors associated with RR/MDR-TB among new pulmonary tuberculosis patients in urban and rural areas of Ukraine in 2017: a retrospective analysis of routine surveillance data," Public Health Panorama, vol. 5, no. 4, pp. 536–547, 2019.
[26] M. Stosic, D. Vukovic, D. Babic et al., “Risk factors for multidrug-resistant tuberculosis among tuberculosis patients in Serbia: a case-control study,” *BMC Public Health*, vol. 18, no. 1, pp. 91–96, 2018.

[27] B. Baya, C. J. Achenbach, B. Kone et al., “Clinical risk factors associated with multidrug-resistant tuberculosis (MDR- TB) in Mali,” *International Journal of Infectious Diseases*, vol. 81, pp. 149–155, 2019.

[28] K. Mehari, T. Asmelash, H. Hailekiros et al., “Prevalence and Factors Associated with Multidrug-Resistant Tuberculosis (MDR- TB) among Presumptive MDR-TB Patients in Tigray Region, Northern Ethiopia,” *Canadian Journal of Infectious Diseases and Medical Microbiology*, vol. 2019, Article ID 2923549, 8 pages, 2019.

[29] E. Whitehouse and J. G. J. Lai, “EFJE,” *Public Health Action. Smok Cessat Interv*, vol. I, no. 2, pp. 37–49, 2018.

[30] R. Alavi-Naini, B. Sharifi-mood, and M. Metanat, “Association between tuberculosis and smoking,” *Tuberc Smok*, vol. 1, no. 2-3, pp. 1–4, 2012.

[31] WHO, *Tobacco smoking and tuberculosis treatment outcomes: a prospective cohort study in Georgia*, pp. 390–399, 2015.

[32] R. N. van Zyl Smit, M. Pai, W. W. Yew et al., “Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD,” *European Respiratory Journal*, vol. 35, no. 1, pp. 27–33, 2010.

[33] WHO, *Addressing poverty in TB control*, WHO/HTM/TB/352, 2005.

[34] S. O. F. Interest and T. N. S. Nipo, “Poverty and tuberculosis: is it truly a simple inverse linear correlation?,” *The European Respiratory Journal*, vol. 33, no. 4, pp. 4-5, 2007.

[35] M. K. Kayomo, E. Hasker, M. Aloni et al., “Outbreak of Tuberculosis and Multidrug-Resistant Tuberculosis, Mbuji-Mayi central Prison, Democratic Republic of the Congo,” *Democratic Republic of the Congo*, vol. 24, no. 11, pp. 2029–2035, 2018.

[36] M. Droznin, A. Johnson, and A. M. Johnson, “Multidrug-resistant tuberculosis in prisons located in former Soviet countries: a systematic review,” *PLoS One*, vol. 12, no. 3, article e0174373, 2017.

[37] WHO, “Tuberculosis in Prisons,” 2020, https://www.who.int/tb/areas-of-work/population-groups/prisons-facts/en/.